Solvay Pharmaceuticals makes a friendly offer to acquire Innogenetics

Solvay Pharmaceuticals SA has made a friendly offer to acquire all of the shares of Innogenetics NV that it doesn’t already own in a cash transaction initially valued at €177.6 million.